Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) has disclosed a series of stock sales executed by its top leadership, specifically Chairman, CEO, and Interim CFO Pham Quang X. The transactions involve the disposal of 18,124 shares of the company's common stock, resulting in a total realized value of $70,351. These sales were conducted over a span of several days during mid-June 2026, marking a significant insider movement within the biotechnology sector.
The specific dates of the transactions were June 11, June 12, and June 15, 2026. On June 11, Mr. Pham sold 1,462 shares at a weighted average price of $4.12 per share. The price range for these shares fluctuated between $4.09 and $4.16. The following day, on June 12, the volume of sales increased substantially. Mr. Pham disposed of 12,996 shares at a weighted average price of $3.94 per share. Individual transaction prices during this session ranged from $3.80 to $4.23. The final set of transactions occurred on June 15, 2026. Mr. Pham sold 3,666 shares at a weighted average price of $3.58 per share. Prices for this batch ranged from $3.22 to $3.81.
All these sales were executed under a Rule 10b5-1 trading arrangement that Mr. Pham adopted on September 25, 2025. This pre-arranged plan allows insiders to trade company stock at predetermined times, regardless of market conditions or material non-public information. Following these transactions, Mr. Pham's direct holding in Cadrenal Therapeutics common stock stands at 132,715 shares. Additionally, he maintains indirect ownership of 200,000 shares through The PVBQ Living Trust. As the Trustee of this entity, Mr. Pham holds sole voting and dispositive power over these assets.
The timing of these sales coincides with a challenging period for the company's stock performance. Cadrenal's shares are currently trading near their 52-week low of $3.27. Over the past year, the stock has experienced a decline of roughly 76%. Despite this substantial drop, some market analysis suggests that the stock may be undervalued at current levels. This perspective places CVKD among potentially attractive opportunities on lists of undervalued stocks. The analysis also highlights 15 additional ProTips for CVKD, offering deeper insights into the company's financial position.
While insider sales are occurring, Cadrenal Therapeutics is making progress in its drug development pipeline. The company recently reported a net loss of $3.0 million for the fourth quarter ending December 31, 2025. This represents an improvement from the $4.2 million loss recorded in the same period of 2024. Furthermore, the company has completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration regarding its investigational treatment, CAD-1005, designed for heparin-induced thrombocytopenia.
Following this meeting, Cadrenal received detailed guidance for a pivotal Phase 3 trial. The trial will be a randomized, blinded, placebo-controlled study. It is set to enroll approximately 120 patients across clinical centers worldwide. The FDA provided specific guidance on protocol design, study population, dosing, background therapy, exposure, safety database, and the primary endpoint of new or worsening thrombotic events. Cadrenal plans to use this guidance to advance directly to the Phase 3 study. The company aims for a New Drug Application submission in 2029 and is actively incorporating FDA feedback into its Phase 3 protocol.
The stock currently trades at $3.33, down $0.37 or 10.00% from the previous close. After hours trading shows a gain of $0.09 or 2.70% to $3.42. This dynamic reflects the ongoing volatility in the biotech sector, where clinical trial outcomes and regulatory decisions heavily influence market sentiment.